Interest in Chaga mushroom supplements is surging across 2025 wellness trends, as consumers seek cleaner, science-aligned alternatives for immune support, inflammation balance, and energy recovery. With dual-extracted fruiting body sourcing and lab-tested transparency, Pilly Labs’ latest formula is gaining attention as a serious contender in the adaptogenic mushroom space—without the hype or filler.
Interest in Chaga mushroom supplements is surging across 2025 wellness trends, as consumers seek cleaner, science-aligned alternatives for immune support, inflammation balance, and energy recovery. With dual-extracted fruiting body sourcing and lab-tested transparency, Pilly Labs’ latest formula is gaining attention as a serious contender in the adaptogenic mushroom space—without the hype or filler.
NEWARK, Del., Aug. 1, 2025 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce Project Call 9.1 for...
Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.
GNC is Now Home to Floyd Mayweather's 101 (One of One) Elite, Science-based Supplement Portfolio
PITTSBURGH, Aug. 1, 2025 /PRNewswire/ -- GNC, the leading health...
WESTCHESTER, Ill., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food and beverage manufacturing industry, today reported its 2025 second quarter results.
The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational...
SAN FRANCISCO, July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the...
SCOTTSDALE, Ariz., July 31, 2025 /PRNewswire/ -- Planet Smoothie® (www.PlanetSmoothie.com) is turning the big 3-0! To celebrate three decades of blending the best tasting smoothies...
SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450 participants have joined the...
SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450 participants have joined the...